The potent cell permeable calpain inhibitor MDL28170 affects the interaction of Leishmania amazonensis with macrophages and shows anti-amastigote activity.

[1]  R. Menna-Barreto,et al.  Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis? , 2016, Parasitology.

[2]  H. Sorimachi,et al.  Calpain research for drug discovery: challenges and potential , 2016, Nature Reviews Drug Discovery.

[3]  J. No.  Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries. , 2016, Acta tropica.

[4]  Qun Chen,et al.  Activation of mitochondrial calpain and increased cardiac injury: beyond AIF release. , 2016, American journal of physiology. Heart and circulatory physiology.

[5]  D. Savoia.  Recent updates and perspectives on leishmaniasis. , 2015, Journal of infection in developing countries.

[6]  C. L. Sodré,et al.  Cruzipain: An Update on its Potential as Chemotherapy Target against the Human Pathogen Trypanosoma cruzi. , 2015, Current medicinal chemistry.

[7]  I. Donkor.  An updated patent review of calpain inhibitors (2012 – 2014) , 2015, Expert opinion on therapeutic patents.

[8]  T. Souto-Padrón,et al.  The Calpain Inhibitor MDL28170 Induces the Expression of Apoptotic Markers in Leishmania amazonensis Promastigotes , 2014, PloS one.

[9]  Jinping Li,et al.  Reduced syncytin-1 expression in choriocarcinoma BeWo cells activates the calpain1–AIF-mediated apoptosis, implication for preeclampsia , 2014, Cellular and Molecular Life Sciences.

[10]  A. L. Santos,et al.  Calpains: potential targets for alternative chemotherapeutic intervention against human pathogenic trypanosomatids. , 2013 .

[11]  V. Maltsev,et al.  Calpain Inhibition Reduces Amplitude and Accelerates Decay of the Late Sodium Current in Ventricular Myocytes from Dogs with Chronic Heart Failure , 2013, PloS one.

[12]  U. Lopes,et al.  Dolabelladienetriol, a Compound from Dictyota pfaffii Algae, Inhibits the Infection by Leishmania amazonensis , 2012, PLoS neglected tropical diseases.

[13]  R. Menna-Barreto,et al.  MDL28170, a Calpain Inhibitor, Affects Trypanosoma cruzi Metacyclogenesis, Ultrastructure and Attachment to Rhodnius prolixus Midgut , 2011, PloS one.

[14]  A. Giudice,et al.  Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-α production , 2010, BMC infectious diseases.

[15]  R. Menna-Barreto,et al.  Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. , 2010, The Journal of antimicrobial chemotherapy.

[16]  C. M. d'Avila-Levy,et al.  Arrested growth of Trypanosoma cruzi by the calpain inhibitor MDL28170 and detection of calpain homologues in epimastigote forms , 2009, Parasitology.

[17]  D. Tsikas.  Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  J. L. Martins,et al.  Antileishmanial activity of MDL 28170, a potent calpain inhibitor , 2006, International Journal of Antimicrobial Agents.

[19]  K. Gull,et al.  Evolutionary Relationships and Protein Domain Architecture in an Expanded Calpain Superfamily in Kinetoplastid Parasites , 2005, Journal of Molecular Evolution.

[20]  James Alexander,et al.  Cysteine peptidases as virulence factors of Leishmania. , 2004, Current opinion in microbiology.

[21]  A. Awasthi,et al.  Immune response to Leishmania infection. , 2004, The Indian journal of medical research.

[22]  L. Ignarro,et al.  Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.